| 000 | 01762 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518075333.0 | ||
| 264 | 0 | _c20201218 | |
| 008 | 202012s 0 0 eng d | ||
| 022 | _a2374-2445 | ||
| 024 | 7 |
_a10.1001/jamaoncol.2019.5367 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDuan, Jianchun | |
| 245 | 0 | 0 |
_aUse of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. _h[electronic resource] |
| 260 |
_bJAMA oncology _c03 2020 |
||
| 300 |
_a375-384 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Systematic Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 700 | 1 | _aCui, Longgang | |
| 700 | 1 | _aZhao, Xiaochen | |
| 700 | 1 | _aBai, Hua | |
| 700 | 1 | _aCai, Shangli | |
| 700 | 1 | _aWang, Guoqiang | |
| 700 | 1 | _aZhao, Zhengyi | |
| 700 | 1 | _aZhao, Jing | |
| 700 | 1 | _aChen, Shiqing | |
| 700 | 1 | _aSong, Jia | |
| 700 | 1 | _aQi, Chuang | |
| 700 | 1 | _aWang, Qing | |
| 700 | 1 | _aHuang, Mengli | |
| 700 | 1 | _aZhang, Yuzi | |
| 700 | 1 | _aHuang, Depei | |
| 700 | 1 | _aBai, Yuezong | |
| 700 | 1 | _aSun, Feng | |
| 700 | 1 | _aLee, J Jack | |
| 700 | 1 | _aWang, Zhijie | |
| 700 | 1 | _aWang, Jie | |
| 773 | 0 |
_tJAMA oncology _gvol. 6 _gno. 3 _gp. 375-384 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamaoncol.2019.5367 _zAvailable from publisher's website |
| 999 |
_c30459399 _d30459399 |
||